Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant…
Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients…
Read More...
Read More...